HistoWiz, a Brooklyn, New York-based leading digital histopathology service company, announced the closing of its $32 million Series A financing.
The round was led by Vivo Capital and included other investors venBio, Asahi Kasei, and Jon Oringer.
The Series A financing will allow HistoWiz to expand our services, build a flagship lab with the latest tissue-sectioning and embedding robots, grow our team to better serve clients, and continue to innovate in this field. We are grateful for the support of our investors to further make an impact within the research community.
Company: HistoWiz, Inc.
Raised: $32.0M
Round: Series A
Funding Month: October 2021
Lead Investors: Vivo Capital
Additional Investors: venBio, Asahi Kasei and Jon Oringe
Company Website: https://home.histowiz.com/
Software Category: PathologyMapTM, an intelligent tissue platform
About the Company: HistoWiz automates histopathology with a rapid turnaround time for researchers in academia, biotech, and pharma. The company processes tissue specimens and digitizes the results, hosting the client's data on a proprietary platform, PathologyMapTM. The company has provided automated histology for over 1000 customers in academia and industry and built PathologyMapTM, an intelligent tissue platform that hosts the world's largest preclinical pathology database. By focusing on automation and AI, HistoWiz turns tissue specimens into publication-quality digital slides online in as little as 48 hours. PathologyMapTM provides customers with online slide viewing, tagging, storage, collaboration, diagnosis, analysis, and the ability to search for pathology data.
Source: https://www.prnewswire.com/news-releases/histowiz-raises-32m-series-a-financing-301403304.html